Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD

Area of Science:

• Hepatology
• Biomarker Discovery
• Metabolic Diseases

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of the global population, with increasing incidence and prevalence.
• Current diagnostic methods for MASLD and its progression to liver fibrosis are limited, necessitating the development of accessible and reliable tools.

Purpose of the Study:

• To review and discuss emerging non-invasive biomarkers for the evaluation and detection of liver fibrosis in patients with MASLD.
• To explore the potential of these biomarkers in improving MASLD diagnosis, patient stratification, and treatment response monitoring.

Main Methods:

• Review of emerging biomarkers including glycation markers (AGEs/sRAGE), lipid mediators (eicosanoids), fetuin-A, collagen turnover markers (PRO-C3, ADAPT), and omic-based technologies.
• Discussion of diagnostic accuracy and potential clinical utility of these novel markers in MASLD patients.

Main Results:

• Several emerging biomarkers have demonstrated high diagnostic accuracy in clinical trials for detecting liver fibrosis in MASLD.
• Omic-based technologies and individualized profiling are driving precision medicine approaches for MASLD.

Conclusions:

• Novel biomarkers hold significant potential for the future management of MASLD, enabling accurate diagnosis and personalized treatment strategies.
• Further rigorous validation and standardized implementation are required for the widespread clinical adoption of these promising biomarkers.